본문 바로가기
KERD
논문KCI 등재

Current Status of Antibiotic Stewardship and the Role of Biomarkers in Antibiotic Stewardship Programs

Kim Chung-Jong
대한감염학회 (The Korean Society Of Infectious Diseases)|2022.12|Infection and Chemotherapy|제54권 제4호|pp. 674-698|DOI 10.3947/ic.2022.0172

2

조회

0

다운로드

5

인용

0

참고문헌

키워드

C-reactive proteinBiomarkerProcalcitoninAntibiotic stewardship
주제분류내과학

초록

The importance of antibiotic stewardship is increasingly emphasized in accordance with the increasing incidences of multidrug-resistant organisms and accompanying increases in disease burden. This review describes the obstacles in operating an antibiotic stewardship program (ASP), and whether the use of biomarkers within currently available resources can help. Surveys conducted around the world have shown that major obstacles to ASPs are shortages of time and personnel, lack of appropriate compensation for ASP operation, and lack of guidelines or appropriate manuals. Sufficient investment, such as the provision of full-time equivalent ASP practitioners, and adoption of computerized clinical decision systems are useful measures to improve ASP within an institution. However, these methods are not easy in terms of both time commitments and cost. Some biomarkers, such as C-reactive protein, procalcitonin, and presepsin are promising tools in ASP due to their utility in diagnosis and forecasting the prognosis of sepsis. Recent studies have demonstrated the usefulness of algorithmic approaches based on procalcitonin level to determine the initiation or discontinuation of antibiotics, which would be helpful in decreasing antibiotics use, resulting in more appropriate antibiotics use.

Abstract

The importance of antibiotic stewardship is increasingly emphasized in accordance with the increasing incidences of multidrug-resistant organisms and accompanying increases in disease burden. This review describes the obstacles in operating an antibiotic stewardship program (ASP), and whether the use of biomarkers within currently available resources can help. Surveys conducted around the world have shown that major obstacles to ASPs are shortages of time and personnel, lack of appropriate compensation for ASP operation, and lack of guidelines or appropriate manuals. Sufficient investment, such as the provision of full-time equivalent ASP practitioners, and adoption of computerized clinical decision systems are useful measures to improve ASP within an institution. However, these methods are not easy in terms of both time commitments and cost. Some biomarkers, such as C-reactive protein, procalcitonin, and presepsin are promising tools in ASP due to their utility in diagnosis and forecasting the prognosis of sepsis. Recent studies have demonstrated the usefulness of algorithmic approaches based on procalcitonin level to determine the initiation or discontinuation of antibiotics, which would be helpful in decreasing antibiotics use, resulting in more appropriate antibiotics use.

참고문헌 (177)

  1. Kingston W, "Antibiotics, invention and innovation", Res Policy, 29, pp.679~710 (2000)
  2. Spellberg B, "The future of antibiotics and resistance", N Engl J Med, 368, pp.299~302 (2013)
  3. Jeong Hyeongseok, "Prevalence of Multidrug-Resistant Organisms and Risk Factors for Carriage among Patients Transferred from Long-Term Care Facilities", Infection and Chemotherapy, 52(2), pp.183~193 (2020), 대한감염학회[DOI]
  4. Alcedo Katherine, "High Prevalence of blaCTX-M in Fecal Commensal Escherichia coli from Healthy Children", Infection and Chemotherapy, 54(1), pp.59~69 (2022), 대한감염학회[DOI]
  5. Choi Young Kyun, "Antibiotic Resistance Patterns of Enterobacteriaceae Isolated from Patients with Healthcare-Associated Infections", Infection and Chemotherapy, 53(2), pp.355~363 (2021), 대한감염학회[DOI]
  6. Kim Bongyoung, "Molecular Epidemiology of Ciprofloxacin-Resistant Escherichia coli Isolated from Community-Acquired Urinary Tract Infections in Korea", Infection and Chemotherapy, 52(2), pp.194~203 (2020), 대한감염학회[DOI]
  7. Kim CJ, "The burden of nosocomial Staphylococcus aureus bloodstream infection in South Korea : a prospective hospital-based nationwide study", BMC Infect Dis, 14, pp.590~ (2014)
  8. Song KH, "Clinical and economic burden of bacteremia due to multidrug-resistant organisms in Korea : a prospective case control study", J Glob Antimicrob Resist, 31, pp.379~385 (2022)
  9. Kim CJ, "Socioeconomic burden of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa in Korea", Sci Rep, 12, pp.13934~ (2022)
  10. Ha DR, "The role of antibiotic stewardship in promoting appropriate antibiotic use", Am J Lifestyle Med, 13, pp.376~383 (2017)
  11. Schuts EC, "Current evidence on hospital antimicrobial stewardship objectives : a systematic review and meta-analysis", Lancet Infect Dis, 16, pp.847~856 (2016)
  12. Ferdous J, "Assessing farmers’ perspective on antibiotic usage and management practices in small-scale layer farms of Mymensingh district, Bangladesh", Vet World, 12, pp.1441~1447 (2019)
  13. McEwen SA, "Antimicrobial resistance : a one health perspective", Microbiol Spectr, 6 (2018)
  14. Mehrotra M, "Enhancing antimicrobial stewardship by strengthening the veterinary drug regulatory framework", Can Commun Dis Rep, 43, pp.220~223 (2017)
  15. Hyeri Seok, "Antimicrobial Therapy and Antimicrobial Stewardship in Sepsis", Infection and Chemotherapy, 52(1), pp.19~30 (2020), 대한감염학회[DOI]
  16. Barlam TF, "Implementing an antibiotic stewardship program : Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America", Clin Infect Dis, 62, pp.e51~e77 (2016)
  17. Yokoe DS, "A compendium of strategies to prevent healthcare-associated infections in acute care hospitals : 2014 updates", Infect Control Hosp Epidemiol, 35, pp.967~977 (2014)
  18. Yoon Young Kyung, "Guidelines on Implementing Antimicrobial Stewardship Programs in Korea", Infection and Chemotherapy, 53(3), pp.617~659 (2021), 대한감염학회[DOI]
  19. Ahmed N, "The Barriers in the implementation of antimicrobial stewardship programs : A systematic review", Research Square, 12 (2019)
  20. Kim B, "Current status of antimicrobial stewardship programmes in Korean hospitals : results of a 2018nationwide survey", J Hosp Infect, 104, pp.172~180 (2020)
  21. Lee MJ, "Status of antimicrobial stewardship programmes in Korean hospitals including small to medium-sized hospitals and the awareness and demands of physicians : a nationwide survey in 2020", J Glob Antimicrob Resist, 26, pp.180~187 (2021)
  22. Doron S, "A nationwide survey of antimicrobial stewardship practices", Clin Ther, 35, pp.758~765 (2013)
  23. Pakyz AL, "Facilitators and barriers to implementing antimicrobial stewardship strategies : Results from a qualitative study", Am J Infect Control, 42(10 Suppl), pp.S257~S263 (2014)
  24. Appaneal HJ, "Facilitators and barriers to antibiotic stewardship : A qualitative study of pharmacists’ perspectives", Hosp Pharm, 54, pp.250~258 (2019)
  25. Wolf J, "Antimicrobial stewardship barriers and goals in pediatric oncology and bone marrow transplantation : A survey of antimicrobial stewardship practitioners", Infect Control Hosp Epidemiol, 37, pp.343~347 (2016)
  26. Gebretekle GB, "Opportunities and barriers to implementing antibiotic stewardship in low and middleincome countries : Lessons from a mixed-methods study in a tertiary care hospital in Ethiopia", PLoS One, 13, pp.e0208447~ (2018)
  27. Hwang Soyoon, "Core Elements for Successful Implementation of Antimicrobial Stewardship Programs", Infection and Chemotherapy, 53(3), pp.421~435 (2021), 대한감염학회[DOI]
  28. Kim Bongyoung, "Professional Status of Infectious Disease Specialists in Korea: A Nationwide Survey", Journal of Korean Medical Science, 37(47), pp.1~11 (2022), 대한의학회[DOI]
  29. Dickstein Y, "Staffing for infectious diseases, clinical microbiology and infection control in hospitals in 2015 : results of an ESCMID member survey", Clin Microbiol Infect, 22, pp.812~ (2016)
  30. Ababneh MA, "A systematic review of antimicrobial stewardship program implementation in Middle Eastern countries", Int J Infect Dis, 105, pp.746~752 (2021)
  31. Greene MH, "Antimicrobial stewardship staffing : How much is enough?", Infect Control Hosp Epidemiol, 41, pp.102~112 (2020)
  32. Park SY, "Human resources required for antimicrobial stewardship activities for hospitalized patients in Korea", Infect Control Hosp Epidemiol, 41, pp.1429~1435 (2020)
  33. Pestotnik SL, "Expert clinical decision support systems to enhance antimicrobial stewardship programs : insights from the society of infectious diseases pharmacists", Pharmacotherapy, 25, pp.1116~1125 (2005)
  34. Hermsen ED, "Implementation of a clinical decision support system for antimicrobial stewardship", Infect Control Hosp Epidemiol, 33, pp.412~415 (2012)
  35. Aulin LBS, "Biomarker-guided individualization of antibiotic therapy", Clin Pharmacol Ther, 110, pp.346~360 (2021)
  36. Nora D, "Biomarker-guided antibiotic therapy-strengths and limitations", Ann Transl Med, 5, pp.208~ (2017)
  37. 김미희, "An Update on Sepsis Biomarkers", Infection and Chemotherapy, 52(1), pp.1~18 (2020), 대한감염학회[DOI]
  38. Tillett WS, "Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus", J Exp Med, 52, pp.561~571 (1930)
  39. Hurlimann J, "The liver as the site of C-reactive protein formation", J Exp Med, 123, pp.365~378 (1966)
  40. Mackiewicz A, "Effects of cytokine combinations on acute phase protein production in two human hepatoma cell lines", J Immunol, 146, pp.3032~3037 (1991)
  41. Weinhold B, "Interleukin-6-dependent and-independent regulation of the human C-reactive protein gene", Biochem J, 327, pp.425~429 (1997)
  42. Pepys MB, "C-reactive protein : a critical update", J Clin Invest, 111, pp.1805~1812 (2003)
  43. Du Clos TW, "C-reactive protein : an activator of innate immunity and a modulator of adaptive immunity", Immunol Res, 30, pp.261~277 (2004)
  44. Monnet E, "Evidence of NI-0101 pharmacological activity, an anti-TLR4 antibody, in a randomized phase I dose escalation study in healthy volunteers receiving LPS", Clin Pharmacol Ther, 101, pp.200~208 (2017)
  45. Vigushin DM, "Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease", J Clin Invest, 91, pp.1351~1357 (1993)
  46. Becker KL, "Clinical review 167 : Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis : a journey from calcitonin back to its precursors", J Clin Endocrinol Metab, 89, pp.1512~1525 (2004)
  47. Reinhart K, "Procalcitonin as a marker of the systemic inflammatory response to infection", Intensive Care Med, 26, pp.1193~1200 (2000)
  48. Landmann R, "Function of soluble CD14 in serum from patients with septic shock", J Infect Dis, 173, pp.661~668 (1996)
  49. Le-Barillec K, "Proteolysis of monocyte CD14 by human leukocyte elastase inhibits lipopolysaccharide-mediated cell activation", J Clin Invest, 103, pp.1039~1046 (1999)
  50. Pavcnik-Arnol M, "Lipopolysaccharide-binding protein, lipopolysaccharide, and soluble CD14 in sepsis of critically ill neonates and children", Intensive Care Med, 33, pp.1025~1032 (2007)
  51. Wu CC, "Comparison of diagnostic accuracy in sepsis between presepsin, procalcitonin, and C-reactive protein : a systematic review and meta-analysis", Ann Intensive Care, 7, pp.91~ (2017)
  52. Hu L, "Diagnostic Value of PCT and CRP for Detecting serious bacterial infections in patients with fever of unknown origin : A systematic review and meta-analysis", Appl Immunohistochem Mol Morphol, 25, pp.e61~e69 (2017)
  53. Lapić I, "Erythrocyte sedimentation rate and C-reactive protein in acute inflammation", Am J Clin Pathol, 153, pp.14~29 (2020)
  54. Tan M, "The diagnostic accuracy of procalcitonin and C-reactive protein for sepsis : A systematic review and meta-analysis", J Cell Biochem, 120, pp.5852~5859 (2019)
  55. Hoeboer SH, "The diagnostic accuracy of procalcitonin for bacteraemia : a systematic review and meta-analysis", Clin Microbiol Infect, 21, pp.474~481 (2015)
  56. Kondo Y, "Diagnostic value of procalcitonin and presepsin for sepsis in critically ill adult patients : a systematic review and meta-analysis", J Intensive Care, 7, pp.22~ (2019)
  57. Tong X, "Presepsin as a diagnostic marker for sepsis : evidence from a bivariate metaanalysis", Ther Clin Risk Manag, 11, pp.1027~1033 (2015)
  58. Zheng Z, "The accuracy of presepsin for the diagnosis of sepsis from SIRS : a systematic review and meta-analysis", Ann Intensive Care, 5, pp.48~ (2015)
  59. Zhang X, "The accuracy of presepsin(sCD14-ST)for the diagnosis of sepsis in adults : a meta-analysis", Crit Care, 19, pp.323~ (2015)
  60. Zhang J, "Diagnostic value of presepsin for sepsis: A systematic review and metaanalysis", Medicine(Baltimore), 94, pp.e2158~ (2015)
  61. Wu J, "Accuracy of presepsin in sepsis diagnosis : A systematic review and meta-analysis", PLoS One, 10, pp.e0133057~ (2015)
  62. Young B, "C-reactive protein : a critical review", Pathology, 23, pp.118~124 (1991)
  63. Bilavsky E, "C-reactive protein as a marker of serious bacterial infections in hospitalized febrile infants", Acta Paediatr, 98, pp.1776~1780 (2009)
  64. Olaciregui I, "Markers that predict serious bacterial infection in infants under 3 months of age presenting with fever of unknown origin", Arch Dis Child, 94, pp.501~505 (2009)
  65. Lacour AG, "Procalcitonin, IL-6, IL-8, IL-1receptor antagonist and C-reactive protein as identificators of serious bacterial infections in children with fever without localising signs", Eur J Pediatr, 160, pp.95~100 (2001)
  66. Maniaci V, "Procalcitonin in young febrile infants for the detection of serious bacterial infections", Pediatrics, 122, pp.701~710 (2008)
  67. Woelker JU, "Serum procalcitonin concentration in the evaluation of febrile infants 2 to 60 days of age", Pediatr Emerg Care, 28, pp.410~415 (2012)
  68. Engel A, "Diagnostic value of procalcitonin serum levels in neutropenic patients with fever : comparison with interleukin-8", Scand J Infect Dis, 31, pp.185~189 (1999)
  69. Gac AC, "Dynamics of procalcitonin and bacteremia in neutropenic adults with acute myeloid leukemia", Leuk Res, 35, pp.1294~1296 (2011)
  70. Giamarellos-Bourboulis EJ, "Assessment of procalcitonin as a diagnostic marker of underlying infection in patients with febrile neutropenia", Clin Infect Dis, 32, pp.1718~1725 (2001)
  71. Jimeno A, "Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia", Cancer, 100, pp.2462~2469 (2004)
  72. 김대용, "The Usefulness of Procalcitonin and C-Reactive Protein as Early Diagnostic Markers of Bacteremia in Cancer Patients with Febrile Neutropenia", Cancer Research and Treatment, 43(3), pp.176~180 (2011), 대한암학회
  73. Koivula I, "Elevated procalcitonin predicts Gram-negative sepsis in haematological patients with febrile neutropenia", Scand J Infect Dis, 43, pp.471~478 (2011)
  74. Persson L, "Use of inflammatory markers for early detection of bacteraemia in patients with febrile neutropenia", Scand J Infect Dis, 36, pp.365~371 (2004)
  75. Prat C, "Evaluation of procalcitonin, neopterin, C-reactive protein, IL-6 and IL-8 as a diagnostic marker of infection in patients with febrile neutropenia", Leuk Lymphoma, 49, pp.1752~1761 (2008)
  76. Aalto H, "Laboratory markers of systemic inflammation as predictors of bloodstream infection in acutely ill patients admitted to hospital in medical emergency", Eur J Clin Microbiol Infect Dis, 23, pp.699~704 (2004)
  77. Albrich WC, "Predicting bacteremia by procalcitonin levels in patients evaluated for sepsis in the emergency department", Expert Rev Anti Infect Ther, 9, pp.653~656 (2011)
  78. Caterino JM, "Bacteremic elder emergency department patients : procalcitonin and white count", Acad Emerg Med, 11, pp.393~396 (2004)
  79. Dwolatzky T, "Procalcitonin in the elderly : normal plasma concentrations and response to bacterial infections", Eur J Clin Microbiol Infect Dis, 24, pp.763~765 (2005)
  80. Guinard-Barbier S, "Is midregional pro-atrial natriuretic peptide(MRproANP)an accurate marker of bacteremia in pyelonephritis?", Biomarkers, 16, pp.355~363 (2011)
  81. Ha YE, "Diagnostic usefulness of procalcitonin as a marker of bacteremia in patients with acute pyelonephritis", Scand J Clin Lab Invest, 73, pp.444~448 (2013)
  82. Hoenigl M, "Diagnostic accuracy of soluble urokinase plasminogen activator receptor(suPAR)for prediction of bacteremia in patients with systemic inflammatory response syndrome", Clin Biochem, 46, pp.225~229 (2013)
  83. 김명희, "Utility of Procalcitonin as an Early Diagnostic Marker of Bacteremia in Patients with Acute Fever", Yonsei Medical Journal, 52(2), pp.276~281 (2011), 연세대학교의과대학
  84. Loonen AJ, "Biomarkers and molecular analysis to improve bloodstream infection diagnostics in an emergency care unit", PLoS One, 9, pp.e87315~ (2014)
  85. Müller F, "Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia : a prospective cohort trial", Chest, 138, pp.121~129 (2010)
  86. Riedel S, "Procalcitonin as a marker for the detection of bacteremia and sepsis in the emergency department", Am J Clin Pathol, 135, pp.182~189 (2011)
  87. Romualdo LG, "Diagnostic accuracy of presepsin(soluble CD14 subtype)for prediction of bacteremia in patients with systemic inflammatory response syndrome in the Emergency Department", Clin Biochem, 47, pp.505~508 (2014)
  88. Su CP, "Predictive model for bacteremia in adult patients with blood cultures performed at the emergency department : a preliminary report", J Microbiol Immunol Infect, 44, pp.449~455 (2011)
  89. Suárez-Santamaría M, "Prognostic value of inflammatory markers(notably cytokines and procalcitonin), nutritional assessment, and organ function in patients with sepsis", Eur Cytokine Netw, 21, pp.19~26 (2010)
  90. Tromp M, "Serial and panel analyses of biomarkers do not improve the prediction of bacteremia compared to one procalcitonin measurement", J Infect, 65, pp.292~301 (2012)
  91. Godnic M, "Diagnostic and prognostic value of sCD14-ST--presepsin for patients admitted to hospital intensive care unit(ICU)", Wien Klin Wochenschr, 127, pp.521~527 (2015)
  92. Ali FT, "Presepsin is an early monitoring biomarker for predicting clinical outcome in patients with sepsis", Clin Chim Acta, 460, pp.93~101 (2016)
  93. Behnes M, "Diagnostic and prognostic utility of soluble CD 14 subtype(presepsin)for severe sepsis and septic shock during the first week of intensive care treatment", Crit Care, 18, pp.507~ (2014)
  94. Cakır Madenci Ö, "Evaluation of soluble CD14 subtype(presepsin)in burn sepsis", Burns, 40, pp.664~669 (2014)
  95. Endo S, "Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study", J Infect Chemother, 18, pp.891~897 (2012)
  96. Enguix-Armada A, "Usefulness of several biomarkers in the management of septic patients : C-reactive protein, procalcitonin, presepsin and mid-regional pro-adrenomedullin", Clin Chem Lab Med, 54, pp.163~168 (2016)
  97. Klouche K, "Diagnostic and prognostic value of soluble CD14 subtype(Presepsin)for sepsis and community-acquired pneumonia in ICU patients", Ann Intensive Care, 6, pp.59~ (2016)
  98. Leli C, "Diagnostic accuracy of presepsin(sCD14-ST)and procalcitonin for prediction of bacteraemia and bacterial DNAaemia in patients with suspected sepsis", J Med Microbiol, 65, pp.713~719 (2016)
  99. Takahashi G, "Presepsin in the prognosis of infectious diseases and diagnosis of infectious disseminated intravascular coagulation : a prospective, multicentre, observational study", Eur J Anaesthesiol, 32, pp.199~206 (2015)
  100. Brenner T, "Methylglyoxal as a new biomarker in patients with septic shock : an observational clinical study", Crit Care, 18, pp.683~ (2014)
  101. Carpio R, "Utility of presepsin(sCD14-ST)as a diagnostic and prognostic marker of sepsis in the emergency department", Clin Chim Acta, 450, pp.169~175 (2015)
  102. Ishikura H, "New diagnostic strategy for sepsis-induced disseminated intravascular coagulation : a prospective single-center observational study", Crit Care, 18, pp.R19~ (2014)
  103. Kweon OJ, "Usefulness of presepsin(sCD14 subtype)measurements as a new marker for the diagnosis and prediction of disease severity of sepsis in the Korean population", J Crit Care, 29, pp.965~970 (2014)
  104. Liu B, "Diagnostic value and prognostic evaluation of presepsin for sepsis in an emergency department", Crit Care, 17, pp.R244~ (2013)
  105. Nakamura Y, "Usefulness of presepsin in the diagnosis of sepsis in patients with or without acute kidney injury", BMC Anesthesiol, 14, pp.88~ (2014)
  106. Sargentini V, "Presepsin as a potential marker for bacterial infection relapse in critical care patients. A preliminary study", Clin Chem Lab Med, 53, pp.567~573 (2015)
  107. Shozushima T, "Usefulness of presepsin(sCD14-ST)measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome", J Infect Chemother, 17, pp.764~769 (2011)
  108. Ulla M, "Diagnostic and prognostic value of presepsin in the management of sepsis in the emergency department : a multicenter prospective study", Crit Care, 17, pp.R168~ (2013)
  109. Vodnik T, "Presepsin(sCD14-ST)in preoperative diagnosis of abdominal sepsis", Clin Chem Lab Med, 51, pp.2053~2062 (2013)
  110. Viasus D, "Biomarkers for predicting short-term mortality in community-acquired pneumonia : A systematic review and meta-analysis", J Infect, 72, pp.273~282 (2016)
  111. Zhang Z, "C-reactive protein as a predictor of mortality in critically ill patients : a meta-analysis and systematic review", Anaesth Intensive Care, 39, pp.854~861 (2011)
  112. Liu D, "Prognostic value of procalcitonin in adult patients with sepsis : A systematic review and meta-analysis", PLoS One, 10, pp.e0129450~ (2015)
  113. Arora S, "Procalcitonin levels in survivors and nonsurvivors of sepsis : Systematic review and meta-analysis", Shock, 43, pp.212~221 (2015)
  114. Yang HS, "Prognostic value of presepsin in adult patients with sepsis : Systematic review and meta-analysis", PLoS One, 13, pp.e0191486~ (2018)
  115. Bajwa EK, "Plasma C-reactive protein levels are associated with improved outcome in ARDS", Chest, 136, pp.471~480 (2009)
  116. Balci C, "Procalcitonin levels as an early marker in patients with multiple trauma under intensive care", J Int Med Res, 37, pp.1709~1717 (2009)
  117. Fraunberger P, "Prognostic value of interleukin 6, procalcitonin, and C-reactive protein levels in intensive care unit patients during first increase of fever", Shock, 26, pp.10~12 (2006)
  118. Gibot S, "Time-course of sTREM(soluble triggering receptor expressed on myeloid cells)-1, procalcitonin, and C-reactive protein plasma concentrations during sepsis", Crit Care Med, 33, pp.792~796 (2005)
  119. Grander W, "C-reactive protein levels and post-ICU mortality in nonsurgical intensive care patients", Chest, 138, pp.856~862 (2010)
  120. Hillas G, "C-reactive protein and procalcitonin as predictors of survival and septic shock in ventilator-associated pneumonia", Eur Respir J, 35, pp.805~811 (2010)
  121. Ho KM, "C-reactive protein concentration as a predictor of in-hospital mortality after ICU discharge : a prospective cohort study", Intensive Care Med, 34, pp.481~487 (2008)
  122. Lobo SM, "C-reactive protein levels correlate with mortality and organ failure in critically ill patients", Chest, 123, pp.2043~2049 (2003)
  123. Meisner M, "Correlation of procalcitonin and C-reactive protein to inflammation, complications, and outcome during the intensive care unit course of multiple-trauma patients", Crit Care, 10, pp.R1~ (2006)
  124. Meng FS, "Serum procalcitonin at the time of admission to the ICU as a predictor of short-term mortality", Clin Biochem, 42, pp.1025~1031 (2009)
  125. Pettilä V, "Predictive value of procalcitonin and interleukin 6 in critically ill patients with suspected sepsis", Intensive Care Med, 28, pp.1220~1225 (2002)
  126. Póvoa P, "C-reactive protein as a marker of ventilator-associated pneumonia resolution : a pilot study", Eur Respir J, 25, pp.804~812 (2005)
  127. Seligman R, "Decreases in procalcitonin and C-reactive protein are strong predictors of survival in ventilator-associated pneumonia", Crit Care, 10, pp.R125~ (2006)
  128. Silvestre J, "Is C-reactive protein a good prognostic marker in septic patients?", Intensive Care Med, 35, pp.909~913 (2009)
  129. Clec’h C, "Differential diagnostic value of procalcitonin in surgical and medical patients with septic shock", Crit Care Med, 34, pp.102~107 (2006)
  130. Dahaba AA, "Procalcitonin for early prediction of survival outcome in postoperative critically ill patients with severe sepsis", Br J Anaesth, 97, pp.503~508 (2006)
  131. Feng L, "Clinical significance of soluble hemoglobin scavenger receptor CD163(sCD163)in sepsis, a prospective study", PLoS One, 7, pp.e38400~ (2012)
  132. Giamarellos-Bourboulis EJ, "Procalcitonin as an early indicator of outcome in sepsis : a prospective observational study", J Hosp Infect, 77, pp.58~63 (2011)
  133. Jain S, "Procalcitonin as a prognostic marker for sepsis : a prospective observational study", BMC Res Notes, 7, pp.458~ (2014)
  134. Kenzaka T, "Use of a semiquantitative procalcitonin kit for evaluating severity and predicting mortality in patients with sepsis", Int J Gen Med, 5, pp.483~488 (2012)
  135. Li Z, "Serum soluble triggering receptor expressed on myeloid cells-1 and procalcitonin can reflect sepsis severity and predict prognosis : a prospective cohort study", Mediators Inflamm, 2014, pp.641039~ (2014)
  136. Magrini L, "Procalcitonin variations after Emergency Department admission are highly predictive of hospital mortality in patients with acute infectious diseases", Eur Rev Med Pharmacol Sci, 17(Suppl 1), pp.133~142 (2013)
  137. Masson S, "Presepsin(soluble CD14 subtype)and procalcitonin levels for mortality prediction in sepsis : data from the Albumin Italian Outcome Sepsis trial", Crit Care, 18, pp.R6~ (2014)
  138. Savva A, "Soluble urokinase plasminogen activator receptor(suPAR)for assessment of disease severity in ventilator-associated pneumonia and sepsis", J Infect, 63, pp.344~350 (2011)
  139. Suberviola B, "Hospital mortality prognostication in sepsis using the new biomarkers suPAR and proADM in a single determination on ICU admission", Intensive Care Med, 39, pp.1945~1952 (2013)
  140. Yin Q, "The role of soluble thrombomodulin in the risk stratification and prognosis evaluation of septic patients in the emergency department", Thromb Res, 132, pp.471~476 (2013)
  141. García de Guadiana-Romualdo LM, "Prognostic value of lipopolysaccharide binding protein and procalcitonin in patients with severe sepsis and septic shock admitted to intensive care", Med Intensiva, 39, pp.207~212 (2015)
  142. Guan J, "Dynamic change of procalcitonin, rather than concentration itself, is predictive of survival in septic shock patients when beyond 10 ng", mL, 2011, pp.36, 570~574
  143. Karlsson S, "Predictive value of procalcitonin decrease in patients with severe sepsis : a prospective observational study", Crit Care, 14, pp.R205~ (2010)
  144. Mat Nor MB, "Procalcitonin clearance for early prediction of survival in critically ill patients with severe sepsis", Crit Care Res Pract, 2014, pp.819034~ (2014)
  145. Schuetz P, "Procalcitonin decrease over 72 hours in US critical care units predicts fatal outcome in sepsis patients", Crit Care, 17, pp.R115~ (2013)
  146. Suberviola B, "Prognostic value of procalcitonin, C-reactive protein and leukocytes in septic shock", Med Intensiva, 36, pp.177~184 (2012)
  147. Tschaikowsky K, "Predictive value of procalcitonin, interleukin-6, and C-reactive protein for survival in postoperative patients with severe sepsis", J Crit Care, 26, pp.54~64 (2011)
  148. Petel D, "Use of C-reactive protein to tailor antibiotic use : a systematic review and meta-analysis", BMJ Open, 8, pp.e022133~ (2018)
  149. Huang HB, "Procalcitonin-guided antibiotic therapy in intensive care unit patients : a systematic review and meta-analysis", Ann Intensive Care, 7, pp.114~ (2017)
  150. Wirz Y, "Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients : a patient-level meta-analysis of randomized trials", Crit Care, 22, pp.191~ (2018)
  151. Gutiérrez-Pizarraya A, "Clinical impact of procalcitonin-based algorithms for duration of antibiotic treatment in critically ill adult patients with sepsis : a meta-analysis of randomized clinical trials", Expert Rev Anti Infect Ther, 20, pp.103~112 (2022)
  152. Meier MA, "Procalcitonin-guided antibiotic treatment in patients with positive blood cultures : A patient-level meta-analysis of randomized trials", Clin Infect Dis, 69, pp.388~396 (2019)
  153. Pepper DJ, "Procalcitonin-guided antibiotic discontinuation and mortality in critically ill adults : a systematic review and meta-analysis", Chest, 155, pp.1109~1118 (2019)
  154. Zhang T, "Procalcitonin-guided antibiotic therapy in critically ill adults : a metaanalysis", BMC Infect Dis, 17, pp.514~ (2017)
  155. Borges I, "Duration of antibiotic therapy in critically ill patients : a randomized controlled trial of a clinical and C-reactive protein-based protocol versus an evidence-based best practice strategy without biomarkers", Crit Care, 24, pp.281~ (2020)
  156. Oliveira CF, "Procalcitonin versus C-reactive protein for guiding antibiotic therapy in sepsis : a randomized trial", Crit Care Med, 41, pp.2336~2343 (2013)
  157. von Dach E, "Effect of C-reactive protein-guided antibiotic treatment duration, 7-day treatment, or 14-day treatment on 30-day clinical failure rate in patients with uncomplicated gram-negative bacteremia : A randomized clinical trial", JAMA, 323, pp.2160~2169 (2020)
  158. Coggins SA, "Use of a computerized C-reactive protein(CRP)based sepsis evaluation in very low birth weight(VLBW)infants : a five-year experience", PLoS One, 8, pp.e78602~ (2013)
  159. Couto RC, "C-reactive protein-guided approach may shorten length of antimicrobial treatment of culture-proven late-onset sepsis : an intervention study", Braz J Infect Dis, 11, pp.240~245 (2007)
  160. Gao HN, "Clinical significance of C-reactive protein values in antibiotic treatment for pyogenic liver abscess", World J Gastroenterol, 16, pp.4871~4875 (2010)
  161. Jaswal RS, "Role of C-reactive protein in deciding duration of antibiotic therapy in neonatal septicemia", Indian Pediatr, 40, pp.880~883 (2003)
  162. Numbenjapon N, "C-reactive protein as a single useful parameter for discontinuation of antibiotic treatment in Thai neonates with clinical sepsis", J Med Assoc Thai, 98, pp.352~357 (2015)
  163. Bloos F, "Effect of sodium selenite administration and procalcitonin-guided therapy on mortality in patients with severe sepsis or septic shock : A randomized clinical trial", JAMA Intern Med, 176, pp.1266~1276 (2016)
  164. de Jong E, "Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients : a randomised, controlled, open-label trial", Lancet Infect Dis, 16, pp.819~827 (2016)
  165. Deliberato RO, "Clinical and economic impact of procalcitonin to shorten antimicrobial therapy in septic patients with proven bacterial infection in an intensive care setting", Diagn Microbiol Infect Dis, 76, pp.266~271 (2013)
  166. Hochreiter M, "Procalcitonin to guide duration of antibiotic therapy in intensive care patients : a randomized prospective controlled trial", Crit Care, 13, pp.R83~ (2009)
  167. Nobre V, "Use of procalcitonin to shorten antibiotic treatment duration in septic patients : a randomized trial", Am J Respir Crit Care Med, 177, pp.498~505 (2008)
  168. Schroeder S, "Procalcitonin(PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis : results of a prospective randomized study", Langenbecks Arch Surg, 394, pp.221~226 (2009)
  169. Shehabi Y, "Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial", Am J Respir Crit Care Med, 190, pp.1102~1110 (2014)
  170. Stolz D, "Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia : a randomised study", Eur Respir J, 34, pp.1364~1375 (2009)
  171. Jensen JU, "Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit : a randomized trial", Crit Care Med, 39, pp.2048~2058 (2011)
  172. Layios N, "Procalcitonin usefulness for the initiation of antibiotic treatment in intensive care unit patients", Crit Care Med, 40, pp.2304~2309 (2012)
  173. Svoboda P, "Can procalcitonin help us in timing of re-intervention in septic patients after multiple trauma or major surgery?", Hepatogastroenterology, 54, pp.359~363 (2007)
  174. Annane D, "Procalcitonin levels to guide antibiotic therapy in adults with non-microbiologically proven apparent severe sepsis : a randomised controlled trial", BMJ Open, 3, pp.e002186~ (2013)
  175. Bouadma L, "Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units(PRORATA trial) : a multicentre randomised controlled trial", Lancet, 375, pp.463~474 (2010)
  176. Wirz Y, "Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients : a patient-level meta-analysis of randomized trials", Crit Care, 22, pp.191~ (2018)
  177. Xiao H, "Potential value of presepsin guidance in shortening antibiotic therapy in septic patients : a multicenter, prospective cohort trial", Shock, 57, pp.63~71 (2022)

관련 논문AI추천

Role of biomarkers in antimicrobial stewardship: physicians’ perspectivesDae Won Park, Hyeri Seok대한내과학회 · The Korean Journal of Internal Medicine2024 · 제39권 제3호Antimicrobial stewardship programs in sepsis treatment: principles, impact, and future directionsEu Suk Kim대한내과학회 · The Korean Journal of Internal Medicine2026 · 제41권 제1호Implementation of Procalcitonin in Antibiotic Stewardship: Derivation of a Consensus Algorithm for Procalcitonin Use in Clinical Practice최준용, Kim Chung-Jong, Kim Hong Bin, Kim Jong Hun, Lee Dong-Gun, Park Dae Won대한감염학회 · Infection and Chemotherapy2022 · 제54권 제4호Core Elements for Successful Implementation of Antimicrobial Stewardship Programs권기태, Hwang Soyoon대한감염학회 · Infection and Chemotherapy2021 · 제53권 제3호Antimicrobial Therapy and Antimicrobial Stewardship in Sepsis박대원, Hyeri Seok, Ji Hoon Jeon대한감염학회 · Infection and Chemotherapy2020 · 제52권 제1호Revolutionising Bacteriology to Improve Treatment Outcomes and Antibiotic StewardshipDavid M. Livermore, John Wain대한감염학회 · Infection and Chemotherapy2013 · 제45권 제1호

이 간행물의 다른 논문 (19건)

Current Status and Prospect of Qualitative Assessment of Antibiotics PrescriptionsLee Raeseok, Kim Yong Chan, Kim Hong Bin, Moon Song Mi, Kim Bongyoung, Park Se Yoonpp. 599-609Clinical Utility of Procalcitonin on Antibiotic Stewardship: A Narrative Review김종훈pp. 610-620Implementation of Procalcitonin in Antibiotic Stewardship: Derivation of a Consensus Algorithm for Procalcitonin Use in Clinical PracticePark Dae Won, Kim Hong Bin, Kim Chung-Jong, Lee Dong-Gun, Kim Jong Hun, 최준용pp. 621-636Core Elements for Implementing Antimicrobial Stewardship Programs in Korean General HospitalsKim Hong Bin, Moon Chisook, Kim Bongyoung, Kwon Ki Tae, 정혜숙, Hwang In Sun, Park Choon-Seon, Shin Ji-Yeon, 이미숙, 김신우, 박경화, 윤영경, 이혁민, Eun Byung Wook, Jeong Su Jin, Kim Hyung-Sook, Kim Yong Chanpp. 637-673Prescription Pattern of Intravenous Fosfomycin in a Provincial Hospital in ThailandAonjumras Wiwarin, Phengjaturat Kamonchanok, Siangsuebchart Onrumpa, Hemapanpairoa Jatapat, Chaisiri Kessarin, Thampithak Anusornpp. 699-710
원문 보기